TNF and hepatocellular carcinoma: From the results of KEGG (Figure 3A, E), it is found that the key targets of TanIIA in the treatment of HCC are mainly involved in the MAPK signal pathway, Transcriptional misregulation in cancer, Hepatitis B, TNF signal pathway, endocrine resistance and other signal pathways, indicating that the therapeutic effect of TanIIA on HCC may be realized through the above pathways.